Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
Novo Nordisk's 27% drop was market overreaction, analysts say
Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
eLife4 天
SFSWAP is a negative regulator of OGT intron detention and global pre-mRNA splicing
This study provides important insights into the regulation of a retained intron in the mRNA coding for OGT, a process known to be regulated by the O-GlcNAc cycling system, and highlights the ...
FiercePharma8 天
2025 forecast: The government crackdown on pharmas' direct-to-consumer outreach marches on
The ways in which pharmaceutical companies market their drugs directly to consumers in the U.S. could face quite the ...
Wall Street Journal1 个月
Intron Biotechnology Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Wall Street Journal1 个月
Intron Technology Holdings Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...